Ortho Mcneil Janssen Drug Patent Portfolio
Ortho Mcneil Janssen owns 1 orange book drug protected by 10 US patents Given below is the list of Ortho Mcneil Janssen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6375978 | Rate controlling membranes for controlled drug delivery devices | 17 Dec, 2018 | Expired |
| US6113938 | Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents | 24 Jul, 2018 | Expired |
| US5932547 | Non-aqueous polar aprotic peptide formulations | 13 Jun, 2017 | Expired |
| US6124261 | Non-aqueous polar aprotic peptide formulations | 13 Jun, 2017 | Expired |
| US6235712 | Non-aqueous polar aprotic peptide formulations | 13 Jun, 2017 | Expired |
| US5728396 | Sustained delivery of leuprolide using an implantable system | 30 Jan, 2017 | Expired |
| US5985305 | Sustained delivery of an active agent using an implantable system | 30 Jan, 2017 | Expired |
| US6132420 | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems | 30 Jan, 2017 | Expired |
| US6156331 | Sustained delivery of an active agent using an implantable system | 30 Jan, 2017 | Expired |
| US6395292 | Sustained delivery of an active agent using an implantable system | 30 Jan, 2017 | Expired |
Latest Legal Activities on Ortho Mcneil Janssen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ortho Mcneil Janssen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Correspondence Address Change
Critical
| 23 Jun, 2016 | US6395292 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Mar, 2015 | US6395292 |
|
Correspondence Address Change
Critical
| 23 Mar, 2015 | US6395292 |
|
Correspondence Address Change
Critical
| 26 Feb, 2008 | US6395292 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 31 Jan, 2008 | US6395292 |
|
Correspondence Address Change
Critical
| 31 Jan, 2008 | US6395292 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 May, 2002 | US6395292 |
|
Recordation of Patent Grant Mailed
Critical
| 28 May, 2002 | US6395292 |
|
Issue Notification Mailed
Critical
| 10 May, 2002 | US6395292 |
| Receipt into Pubs | 02 May, 2002 | US6395292 |
|
Application Is Considered Ready for Issue
Critical
| 22 Apr, 2002 | US6395292 |
|
Issue Fee Payment Received
Critical
| 15 Apr, 2002 | US6395292 |
|
Issue Fee Payment Verified
Critical
| 15 Apr, 2002 | US6395292 |
| Workflow -Received 85b - Unmatched | 15 Apr, 2002 | US6395292 |
| Receipt into Pubs | 15 Mar, 2002 | US6395292 |
Ortho Mcneil Janssen's Family Patents
Ortho Mcneil Janssen Drug List
Given below is the complete list of Ortho Mcneil Janssen's drugs and the patents protecting them.
1. Viadur
Viadur is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6375978 | Rate controlling membranes for controlled drug delivery devices |
17 Dec, 2018
(6 years ago)
| Expired |
| US6113938 | Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents |
24 Jul, 2018
(6 years ago)
| Expired |
| US5932547 | Non-aqueous polar aprotic peptide formulations |
13 Jun, 2017
(7 years ago)
| Expired |
| US6124261 | Non-aqueous polar aprotic peptide formulations |
13 Jun, 2017
(7 years ago)
| Expired |
| US6235712 | Non-aqueous polar aprotic peptide formulations |
13 Jun, 2017
(7 years ago)
| Expired |
| US5728396 | Sustained delivery of leuprolide using an implantable system |
30 Jan, 2017
(7 years ago)
| Expired |
| US5985305 | Sustained delivery of an active agent using an implantable system |
30 Jan, 2017
(7 years ago)
| Expired |
| US6132420 | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
30 Jan, 2017
(7 years ago)
| Expired |
| US6156331 | Sustained delivery of an active agent using an implantable system |
30 Jan, 2017
(7 years ago)
| Expired |
| US6395292 | Sustained delivery of an active agent using an implantable system |
30 Jan, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viadur's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List